A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of AER-271 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs AER-271 (Primary)
- Indications Brain oedema
- Focus Adverse reactions; First in man
- Sponsors Aeromics
- 26 Jul 2018 New trial record
- 09 Jul 2018 According to an Aeromics media release, the data obtained in this study will be used to inform the design of planned phase 2 trial in severe ischemic stroke patients with Large Hemispheric Infarction (LHI).
- 09 Jul 2018 According to an Aeromics media release, the first cohort was dosed on June 26, 2018 and company expects to complete the trial in May 2019.